2007 earnings ahead of guidance Sharp rise in proposed dividend
Paris, February 12, 2008Adjusted net income excluding selected items1Q4 2007:€1,429 million (up 4.5%), i.e. €1.07 per share (up 5.9%, or up 18.3% in U.S. dollars(2))FY 2007:€6,961 million (up 5.9%), i.e. €5.17 per share (up 5.9%, or up 15.7% in U.S. dollars(2))In order to give a representation of our underlying economic performance, we present and explain an adjusted1 income statement. We also report adjusted net income and adjusted EPS (excluding selected items) in U.S. dollars2 in order to facilitate comparisons with the majority of major pharmaceutical groups. The 2007